Month: May 2020

Heat Biologics Presents Positive Survival Benefit for HS-110 in Combination with Nivolumab in Phase 2 Lung Cancer Trial at 2020 American Society of Clinical Oncology (ASCO) Annual Meeting

Median overall survival of 28.7 months in previously treated checkpoint inhibitor naïve non-small cell lung cancer patients Significantly greater median...

error: Content is protected !!